Drug Interaction of Methotrexate with its Adjuvant Drugs for Treatment of Rheumatoid Arthritis
Keywords:
Methotrexate (MTX), Rheumatoid Arthritis, Drug-Drug Interaction, Poly-therapy, ADRsAbstract
Methotrexate (MTX) is used as a DMARDs for some autoimmune illnesses, inclusive of rheumatoid arthritis, juvenile dermatomyositis, psoriasis, psoriatic arthritis and plenty of sorts of vacuities. Low-dose, weekly MTX (10 to 25 mg/week) used as both monotherapy or in mixture with other drugs, has an advanced efficacy profile as defined in placebo-managed trials and comparable efficacy to different medicines which include anti-TNF remedy. Patients suffering from rheumatoid arthritis (RA) may have some comorbid conditions that require a combination of a lot of medicinal drugs. For these comorbidities, prescription show polypharmacy and these medicines may additionally regulate the efficacy or growth of the toxicity of methotrexate (MTX). Interactions among drugs (DDIs) among the prescribed drugs are the reason behind the ADRs and these adverse effects are commonly seen in the aged patients (above 65)
due to poly-pharmacy in prescription. In truth, poly-therapy boom the complexity of the therapeutic management and thereby the risk of a clinically applicable drug interaction. In this review, we report the interactions between MTX and the other tablets commonly used in the control of rheumatoid arthritis. The usage of google scholar, PubMed, PCM, NCBI website and reference lists. we studied the study material posted until 2019 and file the most common drugdrug interaction founds in the prescription of RA patients treating with MTX. In the context of a cure for MTX and NSAIDs like COX-1, COX-2 inhibitor, and among glucocorticoids or immunosuppressive medicinal products e.g., azathioprine, and cyclosporine, clinically important DDIs are identified. DDIs play a major role in both the production of ADRs and therapeutic failure in the treatment of MTX and specific medications.
References
Finckh A. “Early inflammatory arthritis versus rheumatoid arthritis”. Curr Opin Rheumatol 21(2009):118-123.
Gor AP, Saksena M. “Adverse drug reactions of nonsteroidal antiinflammatory drugs in orthopedic patients”. Int J Res Pharmacol Pharmacother 2(2011):26.
Lapeyre‐Mestre M, Grolleau S, Montastruc JL. “Association Française des Centres Régionaux de Pharmacovigilance (CRPV). Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002– 2006”. Fundam Clin Pharmacol 27 (2013):223-30.
Lapeyre‐Mestre M, De Castro AM, Bareille MP, Pozo JG, Requejo AA, et al. “Non‐steroidal anti‐inflammatory drug‐related hepatic damage in France and Spain: analysis from national spontaneous reporting systems”. Fundam Clin Pharmacol 20(2006):391-395.
Rodriguez-Merchan EC. “Topical therapies for knee osteoarthritis”. J Postgrad Med130(2018) 607-612.
Alawi K, Keeble J. “The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation”. Int J Res Pharmacol Pharmacother 125 (2010):181-95.
Hench PS, Kendall EC, Slocumb CH, Polley HF. “Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions: A study in clinical physiology”. Arch Intern Med 85 (1950):545-666.
Byron MA, Mowat AG. “Corticosteroid prescribing in rheumatoid arthritis—the fiction and the fact”. Rheumatology 24 (1985):164-166.
Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, et al. “Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events”. Am J Med 96 (1994):115-123.
Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, et al. “Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and metaanalysis”. Jama 320(2018):2564-2579.
Lyseng-Williamson KA. “Anakinra in Still’s disease: a profile of its use”. Drugs Ther Perspect 34(2018):543-553.
Abbasi M, Mousavi MJ, Jamalzehi S, Alimohammadi R, Bezvan MH, et al. “Strategies toward rheumatoid arthritis therapy; the old and the new”. J Cell Physiol 234(2019):10018-10031.
Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. “Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network metaanalysis”. J Manag Care Spec Pharm 21(2015):409-423.
Singh JA, Hossain A, Ghogomu ET, Mudano AS, Tugwell P, et al. “Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA) ”. Cochrane Database Syst Rev (2016):12437.
Jansen JP, Buckley F, Dejonckheere F, Ogale S. “Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs–a systematic review and network meta-analysis”. Health Qual Life Outcomes 12(2014):102.
Guyot P, Taylor P, Christensen R, Pericleous L, Poncet C, et al. “Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis”. Arthritis Res Ther 13(2011):204.
Gallelli L, Ferreri G, Colosimo M, Pirritano D, Guadagnino L, et al. “Adverse drug reactions to antibiotics observed in two pulmonology divisions of Catanzaro, Italy: a six-year retrospective study”. Pharmacol Res 46(2002):395-400.
Gallelli L, Guadagnino V, Caroleo B, Marigliano N, De Sarro GB, et al. “Bilateral skin ulceration after injection of pegylated interferon-α-2b in a patient with chronic hepatitis C”. Clin Drug Invest 23(2003):615-619.
Gallelli L, Ferraro M, Mauro GF, De Sarro G. “Generalised Dermatitis Induced by Pegylated Interferon-α-2b in a Patient Infected with Genotype-1 Hepatitis C Virus. Clin Drug Invest 25(2005):281-284.
Scicchitano F, Giofre C, Palleria C, Mazzitello C, Ciriaco M, et al. “Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis”. Res Med Sci17(2012):872-875.
Chungi VS, Bourne DW, Dittert LW. “Drug absorption VIII: kinetics of GI absorption of methotrexate”. Pharm Sci 67(1978):560-561.
Henderson ES, Adamson RH, Oliverio VT. “The metabolic fate of tritiated methotrexate: II Absorption and excretion in man”. Cancer Res 25(1965):1018-1024.
Balis FM, Savitch JL, Bleyer WA. “Pharmacokinetics of oral methotrexate in children. Cancer Res 43 (1983):2342-2345.
Kearney PJ, Light PA, Preece A, Mott MG. “Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia”. Cancer Chemother Pharmacol 3(1979):117-120.
Fabre G, Seither R, Goldman ID. “Hydroxylation of 4-aminoantifolates by partially purified aldehyde oxidase from rabbit liver”. Biochem Pharmacol 35(1986):1325-1330.
Johns DG, Loo TL. “ Metabolite of 4-amino-4-deoxy-N10- methylpteroylglutamic acid (methotrexate) ”. Pharm Sci 56(1967):356- 359.
Erttmann R, Bielack S, Landbeck G. “Kinetics of 7-hydroxymethotrexate after high-dose methotrexate therapy”. Cancer Chemother Pharmacol 15(1985):101-104.
JacobsSA,StollerRG,ChabnerBA,JohnsDG.“7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate”. Clin Invs 57(1976):534-538.
Breithaupt H, Kuenzlen E. “Infusions of High-Dose Methotrexate”. Cancer Treat Rep 66(1982):1733-1711.
Zaharko DS, Dedrick RL. “Pharmacokinetics of methotrexate in animals and man”. InFolate Antagonists as Therapeutic Agents 2(1984):97-163.
Chan ES, Cronstein BN. “Methotrexate—how does it really work? ”. Nat Rev Rheumatol 6(2010):175-178.
Nesher G, Moore TL, Dorner RW. “In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine”. Ann Rheum Dis50(1991):637-641.
Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. “Drug-drug interactions among elderly patients hospitalized for drug toxicity”. JAMA 289 (2003):1652-1658.
McDonnell PJ, Jacobs MR. “Hospital admissions resulting from preventable adverse drug reactions”. Ann Pharmacother36(2002):1331-1336.
Strandell J, Bate A, Lindquist M, Edwards IR. “Swedish, Finnish, Interaction X-referencing Drug-drug Interaction Database (SFINX Group). Drug-drug interactions-A preventable patient safety issue”. Br J Clin Pharmacol 65(2007):144-146.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. “Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients”. BMJ 329(2004):15-19.
Aparasu R, Baer R, Aparasu A. “Clinically important potential drug-drug interactions in outpatient settings”. Res Social Adm Pharm 3(2007):426-437.
Svanström H, Lund M, Melbye M, Pasternak B. “Concomitant use of low‐dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis”. Pharmacoepidemiol Drug Saf 27 (2018):885-893.
Statkevich PA, Fournier DJ, Sweeney KR. “Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney”. Pharmacol Exp Ther 265(1993):1118-1124.
Daly H, Boyle J, Roberts C, Scott G. “Interaction between methotrexate and non-steroidal anti-inflammatory drugs”. The Lancet 327(1986):557.
Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE. “Aspirin alters methotrexate disposition in rheumatoid arthritis patients”. Arthritis Rheum 34(1991):1514-1520.
Zuik M, Mandel MA. “Methotrexate--salicylate interaction: a clinical and experimental study”. Surg Forum 26(1975):567.
Stewart CF, Fleming RA, Arkin CR, Evans WE. “Coadministration of naproxen and low‐dose methotrexate in patients with rheumatoid arthritis”. Clin Pharmacol Ther 47(1990):540-546.
Furst DE, Herman RA, Koehnke R, Ericksen N, et al. “Effect of aspirin and sulindac on methotrexate clearance”. J Pharm Sci (1990)79(9):782- 786.
Frenia M L, Long KS, Hartshorn EA. “Methotrexate and Nonsteroidal Antiinflammatory Drug Interactions”. Ann Pharmacother 26(1992):234–237.
Honjo H, Uwai Y, Iwamoto K. “Inhibitory Effect of Selective Cyclooxygenase-2 Inhibitor Etoricoxib on Human Organic Anion Transporter 3 (hOAT3) ”. Drug Metab Lett 5(2011):137–140.
Rachana PR, Anuradha HV, Mounika R. “Stevens Johnson syndrometoxic epidermal necrolysis overlap secondary to interaction between methotrexate and etoricoxib: A case report”. J Clin Diagn Res JCDR 9 (2015):FD01.
Maeda A, Tsuruoka S, Ushijima K, Kanai Y, Endou H. “Drug interaction between celecoxib and methotrexate in organic anion transporter 3–transfected renal cells and in rats in vivo”. Eur J Pharmacol (2010)640:168–171.
Karim A,Tolbert D, Piergies A, Hunt T, Hubbard R, et al. “Celecoxib, a specific cox-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin”. J Rheumatol 41(1998):315.
Schwartz JI, Agrawal NGB, Wong PH, Bachmann KA, Porras AG, et al. “Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients”. J Clin Pharmacol 41 (2001): 1120–1130.
Carmichael SJ, Beal J, Day RO, Tett SE. “Combination therapy with methotrexate and hydroxychloroquine for rheumatoid”. J Rheumatol 29(2002):2077-2083.
Chan J, Sanders DC, Du L, Pillans PI. “ Leflunomide-associated pancytopenia with or without methotrexate”. Ann Pharmacother 38(2004): 1206-1211.
McEwen J, Purcell PM, Hill RL, Calcino LJ, Riley CG. “The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate”. Pharmacoepidemiol Drug Saf 16(2007):65-73.
Toyokawa Y, Kingetsu I, Yasuda C, Yasuda J, Yoshida K, et al. “Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient”. Mod Rheumatol 17(2007):436-440.
Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, et al. “A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis”. Rheumatol (2000)39:655-665.
Elkayam O, Yaron M, Zhukovsky G, Segal R, Caspi D. “Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. Rheumatol Int (1997)17:49-53.
Saurat JH, Guérin A, Andrew PY, Latremouille-Viau D, Wu EQ, et al. “High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice”. Dermatol 220(2010); 128-137.
Gerards AH, Landewe RB, Prins AP, Bruijn GA, Laan RF, et al. “Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial”. Ann Rheum Dis 62(2003):291-296.
Fuksa L, Brcakova E, Kolouchova G, Hirsova P, Hroch M, et al. “Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats”. Toxicology 267(2010:165-171.
Lin H, Abida WM, Sauer RT, Cornish VW. “Dexamethasone− Methotrexate: An Efficient Chemical Inducer of Protein Dimerization In Vivo”. Amer Chem Soci (2000) 122:4247-4248.
Wolff JE, Hauch H, Kühl J, Egeler RM, Jürgens H. “Dexamethasone increases hepatotoxicity of MTX in children with brain tumors”.
